Attana technology applied in malaria vaccine development to determine the neutralizing effect of sera
In a new publication in “Vaccines” from Department of Immunology and Microbiology, Centre for translational Medicine & Parasitology at Copenhagen University, Attana technology has been applied to determine the interaction kinetics between antibodies from vaccinated mice and the pathogen antigen used for the vaccines. This provides valuable information for creating a vaccine with optimal neutralizing effect and hence a high level of protection for the individuals.
In the study two types of vaccines have been compared. A traditional pathogen peptide vaccine and capsid Virus-Like Particles (cVLP) vaccine. In the latter the cVLP is coated with the peptide. The overall result demonstrates the potential of the cVLP platform to create efficient vaccines.
Attana technology has been applied to determine the interaction kinetics between the mice antibodies and the peptide. The mice antibodies have been extracted from mice sera and antibodies from several mice have been pooled (mixed) before the kinetic analysis. Thereby the response at a group level can be determined. (It is also possible to analyze on an individual level by analyzing the mice sera directly).
At Attana, we would like to pinpoint the difference between the two vaccine versions with respect to antibody interaction kinetics, in particular the off-rate. In the picture below, the interaction kinetics for different concentrations are presented. The off-rate of the cVLP vaccine (the right graph) is very slow, almost parallel with the X-axis, whereas in the peptide vaccine, the off-rate has a visible decreasing signal. This shows that the antibodies from the cVLP vaccine stays significantly longer on the peptide compared to the antibodies from the peptide vaccine. The cVLP antibodies thereby efficiently blocks the peptide from interacting with other molecules in the body, hence inhibits the infection.
The application and the results are related to Attana Immunity Profiles, where a slow off-rate of an individual’s sera antibodies is one of the necessary parameters to have a good level of protection against a given pathogen.
For more information, please contact:
Teodor Aastrup, CEO
ir@attana.com
+46 708 86 23 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
